SiBone
SIBN Healthcare Medical Devices
SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow SIBN
SiBone (SIBN) Beneish M-score
SiBone's Beneish M-score for fiscal 2025 is −3.08; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.08 | (0.34) |
| FY2024 | −2.74 | 0.05 |
| FY2023 | −2.79 | (0.05) |
| FY2022 | −2.74 | (6.58) |
| FY2021 | 3.84 | 6.65 |
| FY2020 | −2.81 | (2.23) |
| FY2019 | −0.58 | 1.88 |
| FY2018 | −2.46 | 0.84 |
| FY2017 | −3.30 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.91 | — | 0.83 | |
| Gross margin index | 0.99 | — | 0.52 | |
| Asset quality index | 0.48 | — | 0.20 | |
| Sales growth index | 1.20 | — | 1.07 | |
| Depreciation index | (0.40) | — | −0.05 | |
| SG&A index | 0.91 | — | −0.16 | |
| Total accruals to total assets | (0.08) | — | −0.36 | |
| Leverage index | 0.94 | — | −0.31 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.08 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| AHCO AdaptHealth Corp. compare | −3.3× |
| IART Integra LifeSciences Holdings Corporation compare | −3.2× |
| VREX VAREX IMAGING compare | −3.1× |
| QDEL QuidelOrtho Corporation compare | −3.1× |
| SIBN SiBone | −3.1× |
| PRCT PROCEPT BioRobotics Corporation compare | −2.9× |
| LMRI Lumexa Imaging Holdings, Inc. compare | −2.7× |
| INMD InMode Ltd. compare | −2.3× |
| BBNX Beta Bionics, Inc. compare | −1.9× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI